Formulations of 4,6,4'-trihydroxy-3'- methoxyaurone

Topical formulations of 4,6,4’-trihydroxy-3’-methoxyaurone in solvents like dimethyl isosorbide address aged skin issues by enhancing skin resilience and elasticity through antioxidant and elastase inhibition, effectively addressing wrinkles and skin appearance concerns.

WO2024233754A2PCT designated stage expired Publication Date: 2024-11-14DEBUT BIOTECHNOLOGY INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/028526
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-10
Filing Date
2024-05-09
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Aged skin experiences decreased keratinocyte proliferation, thinning, impaired barrier formation, and reduced collagen synthesis, leading to wrinkles, bruising, and decreased skin resilience, with existing treatments lacking effective topical solutions for improving skin condition and appearance.

Method used

Topical formulations of 4,6,4’-trihydroxy-3’-methoxyaurone, dissolved in solvents like dimethyl isosorbide, are used to enhance skin and hair resiliency, elasticity, and protect against damage, formulated into stable emulsions for effective administration.

Benefits of technology

The formulations demonstrate antioxidant activity, elastase enzyme inhibition, and glycation inhibition, leading to improved skin elasticity, reduced wrinkles, and enhanced aesthetic appearance by modulating gene expression related to collagen production and inflammation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000012_0001
    Figure IMGF000012_0001
  • Figure IMGF000043_0001
    Figure IMGF000043_0001
  • Figure IMGF000013_0001
    Figure IMGF000013_0001
Patent Text Reader

Abstract

The invention provides compositions comprising 4,6,4'-trihydroxy-3'-methoxyaurone. The compositions of the invention may be administered topically, on the skin of the subject. The invention further provides methods of administration of compositions comprising 4,6,4'- trihydroxy-3'-methoxyaurone for amelioration or treatment of a. skin condition. The compositions of the invention may also be applied for improving the general appearance of the skin.
Need to check novelty before this filing date? Find Prior Art

Description

[0001]Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application FORMULATIONS OF 4,6,4’-TRIHYDROXY-3’-METHOXYAURONE I. FIELD OF THE INVENTION The invention is related to formulations of 4,6,4’-trihydroxy-3’-methoxyaurone and^ methods of using the formulations for topical conditions in a subject. II. BACKGROUND OF THE INVENTION Mammalian epidermis and its appendages (e.g., hair, nail, sebaceous and sweat glands) provide a barrier to keep harmful elements out of the body and essential body fluids in. As the^ first line of defense against the various physical traumas of the environment, the epidermis must protect itself as well as the underlying tissues. The epidermis is also exposed to mutagenic ultraviolet radiation. In nonhaired or sparsely haired regions such as most human skin, the epidermis is thicker than that of furred skin, and in these locations the skin functions primarily in a protective role. The constant assaults on the epidermis necessitate self-renewal, making^ the epidermis a prime example of an adult tissue that undergoes continual and rapid flux. Aged skin differs from youthful skin both in appearance and in function. The aged epidermis demonstrates decreased keratinocyte proliferation and is physically thinner, but mostly from decline of the rete ridges. In addition to thinning, aging slows wound healing, prolongs epidermal turnover, and impairs barrier formation. The skin appears thin, wrinkled,^ bruised, and rough. Wrinkling and bruising can also result from aging-related changes in the dermis. The dermis, too, is characteristically thinner in aged persons. Aged fibroblasts are less likely to synthesize normal amounts of collagen, elastin, laminin glycosaminoglycans, and fibronectin. The dermis can, in such cases, lack elasticity, strength, vessel support, remodeling abilities, and ground substances. For example, rete ridges can be effaced, and basal cells can^ no longer display villous projections into the dermis. Epidermal cell turnover is reduced up to 50% in the aged as compared to youth. For example, melanocyte numbers can decrease 8-20% per decade. There are fewer Langerhans cells in the aged, and those present are often functionally impaired. Collagen synthesis decreases, for example, up to 30% within 4 years of menopause in women. The^ numbers of collagen and elastic fibers are also decreased. The dermis can also become less echogenic to ultrasounds, consistent with changes in collagen and elastic tissues. 1 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application III. SUMMARY OF THE INVENTION The invention relates to compositions of 4,6,4’-trihydroxy-3’-methoxyaurone, and methods of using the compositions for treating, protecting, and / or altering (e.g., improving) the condition and / or aesthetic appearance of skin, including, for example, treating, preventing,^ ameliorating, reducing and / or eliminating fine lines and / or wrinkles of skin and / or improving the aesthetic appearance of fine lines and / or wrinkles of skin. In certain embodiments, the compositions of the invention lead to increase in skin and / or hair resiliency. In certain embodiments, the compositions of the invention lead to increase in elasticity of the skin. In certain embodiments, the compositions of the invention prevent skin damage. ^ Topical administration of 4,6,4’-trihydroxy-3’-methoxyaurone was not known in the field. In particular, the topical administration of 4,6,4’-trihydroxy-3’-methoxyaurone for improving the condition of skin, including enhancing the appearance of the skin, by topical administration of a composition comprising an effective amount of 4,6,4’-trihydroxy-3’-methoxyaurone was not known in the field. Beneficially, the invention recognizes, for the first time, that topical^ compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone may be used for improving the condition of the skin or for treatment of any ailment related to the skin of a subject. In one aspect, the invention includes a composition for topical administration comprising an effective amount of 4,6,4’-trihydroxy-3’-methoxyaurone. The effective amount of 4,6,4’-trihydroxy-3’- methoxyaurone is an amount of 4,6,4’-trihydroxy-3’-methoxyaurone that would be effective in^ treating, ameliorating, or otherwise impacting the underlying condition of the skin. The invention recognizes that 4,6,4’-trihydroxy-3’-methoxyaurone is poorly soluble or insoluble in water. The invention also recognizes that 4,6,4’-trihydroxy-3’-methoxyaurone is also poorly soluble or insoluble in oil, for example, the 4,6,4’-trihydroxy-3’-methoxyaurone is insoluble in Helianthus Annuus (Sunflower) Seed Oil. In certain embodiments of the invention, 4,6,4’-trihydroxy-3’-^ methoxyaurone is dissolved in a solvent selected from a group consisting of: dimethyl isosorbide, ethoxydiglycol, isopropyl lauryl sarcosinate, pentylene glycol, propanediol, 1,2-hexanediol, and / or butylene glycol. In certain preferred embodiments, 4,6,4’-trihydroxy-3’-methoxyaurone is dissolved in dimethyl isosorbide. In certain embodiments, the composition comprising 4,6,4’- trihydroxy-3’-methoxyaurone is anhydrous. In certain embodiments, the composition comprises^ oil as the only solvent. 2 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application In certain embodiments, 4,6,4’-trihydroxy-3’-methoxyaurone is dissolved in a solvent selected from a group consisting of: 1,2 heptanediol, 1,2 hexanediol, 1,2 propanediol, butylene glycol, C15-19 alkane, capric / caprylic triglyceride, dibutyl adipate, diisopropyl adipate, dimethyl isosorbide, dipropylene glycol, ethanol, ethoxydiglycol, isoamyl laurate, isohexadecane,^ isopentyldiol, isopropyl myristate, isoproyl lauryl sarcosinate, jojoba oil, meadowfoam seed oil, mineral oil, neopentyl glycol diethylhexanoate, octyldodecanol, oleyl alcohol, pentylene glycol, phenylpropanol, polysorbate 20, propanediol, safflower seed oil, squalene, sunflower oil, t-butyl alcohol, tributyl citrate, tributyl-O-acetylcitrate, tri-C15-19alkyl citrate, triethyl citrate, triethyl O- acetylcitrate, and triisostearin. ^ Thus, in certain embodiments, the composition comprises an emulsion. Preferably, the emulsion is oil / water emulsion. In certain embodiments, the composition further comprises dimethyl isosorbide. In certain embodiments, 4,6,4’-trihydroxy-3’-methoxyaurone is dissolved in dimethyl isosorbide. The compositions of the invention are wherein the composition are stable under storage for at least 3 months. This is beneficial because the compositions of the invention^ may be stored prior to administration to the subjects. In certain embodiments, wherein the compositions of the invention have less than about 20% degradation when stored at 4 ^ or 25 ^ for two (2) months. In certain embodiments, the compositions of the invention have less than about 25% degradation when stored at 40 ^ or 50 ^ for two (2) months. In certain embodiments, the composition comprises 4,6,4’-trihydroxy-3’-methoxyaurone^ in a concentration of about 5 nM to about 2500 nM. In certain embodiments, the composition comprises 4,6,4’-trihydroxy-3’-methoxyaurone in a concentration of about 10 nM to about 2000 nM. In certain embodiments, the composition comprises 4,6,4’-trihydroxy-3’-methoxyaurone in a concentration of about 20nM nM to about 1000 nM. In certain embodiments, the composition comprises 4,6,4’-trihydroxy-3’-methoxyaurone in a concentration of about 10 nM to about 20 nM.^ In certain embodiments, in the compositions of the invention, 4,6,4’-trihydroxy-3’-methoxyaurone is present in a concentration of about 0.0001% to about 5.0% w / w. In certain other embodiments, 4,6,4’-trihydroxy-3’-methoxyaurone is present in a concentration of 0.0005% to about 2.0% w / w. In certain other embodiments, 4,6,4’-trihydroxy-3’-methoxyaurone is present in a concentration of 0.0007% to about 1.0% w / w. In certain other embodiments, 4,6,4’-trihydroxy-3’-^ methoxyaurone is present in a concentration of 0.001% to about 0.75% w / w. In certain other 3 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application embodiments, 4,6,4’-trihydroxy-3’-methoxyaurone is present in a concentration of 0.001% to about 0.75% w / w. In certain other embodiments, 4,6,4’-trihydroxy-3’-methoxyaurone is present in a concentration of about 0.5% w / w. In certain aspects, the compositions of the invention may be administered as a topical^ composition on the skin of the subject. The compositions of the invention may be included in any formulation suitable for topical administration. In certain embodiments, the composition of the invention is a fluid, emulsion, encapsulation, suspension, solid, semi-solid, jelly, paste, gel, hydrogel, ointment, lotion, emulsion, cream, foam, mousse, liquid, spray, suspension, dispersion, powder, aerosol, color cosmetic, and / or hair treatment. In certain embodiments, the compositions^ of the invention also include excipients. These excipients may be selected from a group consisting of: solvent, emulsifier, preservative, antioxidant, emollient, thickening agent, penetration enhancer, surfactant, diluent, filler, carrier, and / or pH control agent. In certain embodiments, the preservative in the composition is an antimicrobial preservative or chelating agent. In certain embodiments, the solvent of the invention is dimethyl isosorbide. ^ The compositions of the invention may be prepared by various methods. As an example, the compositions may be prepared by dissolving, dispersing, etc. 4,6,4’-trihydroxy-3’- methoxyaurone as provided herein and optional excipients in a carrier (e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol or the like) or a solvent to form a solution, colloid, liposome, emulsion, complexes (including inclusion complexes), coacervate, or suspension. In certain^ embodiments, the compositions of the current invention can also contain additional excipients such as wetting agents, emulsifying agents, co-solvents, solubilizing agents, pH buffering agents, and the like (e.g., sodium acetate, sodium citrate, cyclodextrins and derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, hydroxyethylpiperazine and the like). In certain embodiments, the compositions of the invention may further include one or more additional^ excipients selected from a group consisting of: carriers, excipients, or diluents including, but not limited to, absorbents, anti-irritants, antibacterials, anti-acne agents, antioxidants, coloring agents / pigments, emollients (moisturizers), emulsifiers, film-forming / holding agents, fragrances, leave-on exfoliants, prescription drugs, preservatives, scrub agents, silicones, skin- identical / repairing agents, slip agents, sunscreen actives, surfactants / detergent cleansing agents,^ penetration enhancers, and thickeners. 4 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application In certain embodiments, the compositions of the invention comprise: 4,6,4’-trihydroxy-3’- methoxyaurone, in an oil / water emulsion, and a preservative. In certain embodiments, the compositions of the invention comprise: 4,6,4’-trihydroxy-3’- methoxyaurone, in an oil / water emulsion, a solvent for solubilizing 4,6,4’-trihydroxy-3’-^ methoxyaurone, and a preservative. In certain embodiments, the compositions of the invention comprise: 4,6,4’-trihydroxy-3’- methoxyaurone, in an oil / water emulsion, a solvent for solubilizing 4,6,4’-trihydroxy-3’- methoxyaurone, a diluent, and a preservative. In certain embodiments, the compositions of the invention comprise: 4,6,4’-trihydroxy-3’-^ methoxyaurone, in an oil / water emulsion, a solvent for solubilizing 4,6,4’-trihydroxy-3’- methoxyaurone, a thickener, optionally a diluent, and a preservative. In certain embodiments, the compositions of the invention comprise: 4,6,4’-trihydroxy-3’- methoxyaurone, in an oil / water emulsion, a solvent for solubilizing 4,6,4’-trihydroxy-3’- methoxyaurone, and one or more excipients selected from the group consisting of: diluents,^ absorbents, antioxidants, emollients, emulsifiers, thickeners, surfactants, and / or preservatives. In certain embodiments, the excipients included in the composition are water, dimethyl isosorbide, glycerin, caprylic / capric triglyceride, propanediol, sunflower seed oil, ethoxydiglycol, squalane, sodium acrylate copolymer, cetearyl alcohol, phenoxyethanol, glyceryl stearate, capryloyl glycerin / sebacic acid copolymer, diheptyl succinate, naringenin, lecithin, decylene^ glycol, pentylene glycol, cetearyl glucoside, shea butter, palmitic acid, arachidyl alcohol, behenyl alcohol, arachidyl glucoside, phenethyl alcohol, 1,2-hexanediol, hydrogenated olive oil, olea europaea (olive) fruit oil, olea europaea (olive) oil unsponifiables, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, citric acid, sodium acetylated hyaluronate, sodium hyaluronate crosspolymer, sodium phytate, hydrolyzed sodium hyaluronate, and / or^ ethylhexylglycerin. In certain aspects, the invention provides that the compositions of the inventions are synergistic. The compositions provided in the invention are beneficial because of their enhanced stability due to the synergistic effects of the ingredients in the composition and the resulting stability and efficacy. In certain embodiments, the invention provides that the compositions of the 5 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application invention are more efficacious and stable as compared to when they are administered or stored as individual ingredients. The compositions of the invention may also act synergistically when administered along with other therapies for treatment of the conditions described herein. In certain aspects of the invention, the compositions comprising 4,6,4’-trihydroxy-3’-^ methoxyaurone demonstrate antioxidant activity. In certain embodiments, the compositions of the invention, the antioxidant activity of 4,6,4’-trihydroxy-3’-methoxyaurone is demonstrated at concentrations of about 0.00005% w / w or higher. Advantageously, the compositions of the invention comprising 4,6,4’-trihydroxy-3’-methoxyaurone, demonstrating antioxidant activity, are effective for treating and / or preventing oxidation damage. In certain embodiments, the^ compositions of the invention comprising 4,6,4’-trihydroxy-3’-methoxyaurone, demonstrating antioxidant activity, are effective for treatment of skin and / or hair damaged by reactive oxygen species and protection from other environmental aggressors that may damage the skin of the subject. In certain other embodiments, the compositions of the invention comprising 4,6,4’- trihydroxy-3’-methoxyaurone, demonstrating antioxidant activity, are effective for prevention of^ skin and / or hair damage by reactive oxygen species, including the damage caused by environmental aggressors. In certain aspects of the invention, the compositions comprising 4,6,4’-trihydroxy-3’- methoxyaurone demonstrate elastase enzyme inhibition. In certain embodiments, the compositions of the invention, the elastase enzyme inhibition activity of 4,6,4’-trihydroxy-3’-methoxyaurone is^ demonstrated at concentrations of about 0.005% w / w or higher. Advantageously, the compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone, demonstrating elastase enzyme inhibition activity, are effective for promoting the elasticity of the skin. In certain embodiments, the compositions of the invention comprising 4,6,4’-trihydroxy-3’-methoxyaurone, demonstrating elastase enzyme inhibition, are effective in reduction of fine lines and / or wrinkles in the skin. In^ certain embodiments, the compositions of the invention comprising 4,6,4’-trihydroxy-3’- methoxyaurone, demonstrating elastase enzyme inhibition, are effective in prevention of formation of fine lines and / or wrinkles in the skin. In certain aspects of the invention, the compositions comprising 4,6,4’-trihydroxy-3’- methoxyaurone demonstrate inhibition of glycation. In certain embodiments, the compositions of^ the invention, the glycation inhibition activity of 4,6,4’-trihydroxy-3’-methoxyaurone is 6 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application demonstrated at concentrations of about 0.0005% w / w or higher. Advantageously, the compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone, demonstrating glycation inhibition activity, are effective for supporting and promoting skin and / or hair resiliency. In certain aspects of the invention, the compositions comprising 4,6,4’-trihydroxy-3’-^ methoxyaurone promote skin lightening and / or brightening. In certain embodiments, the compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone at least a concentration of 0.01% w / w, have at least about 10% higher L value (reflecting the lightening of the skin), as compared to skin treated with a corresponding composition lacking 4,6,4’-trihydroxy-3’-methoxyaurone. In certain aspects of the invention, a composition comprising 4,6,4’-trihydroxy-3’-^ methoxyaurone modulates expression of one more genes that is related to a topical condition. In certain embodiments, administration of composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone alters one or more of a function related with the modulated genes, wherein the one or more function is selected from the group consisting of: (i) collagen expression, (ii) formation of fines lines or wrinkles on the skin, (iii) inflammation, (iv) melanin synthesis, and (v) collagen^ degradation. In certain embodiments, the one or more genes are selected from a group consisting of: (i) INHBA, (ii) PTGS2, (iii) IL1R2, (iv) IL36RN, (v) IL1A, (vi) IL1B, (vii) IL36G, (viii) CTGF, (ix) IL6, (x) MMP3, and (xi) MMP9. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone leads to up-regulation of CTGF. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’-^ methoxyaurone leads to down-regulation of INHBA, PTGS2, IL1R2, IL36RN, IL1A, IL1B, IL36G, IL6, MMP3, and / or MMP9. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone have an antiaging effect on the skin. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone inhibits melanogenesis. In certain embodiments, administration of a composition comprising^ 4,6,4’-trihydroxy-3’-methoxyaurone has an anti-inflammatory effect, thereby, reducing inflammation and improving the appearance of the skin. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone leads to up-regulation of CTGF and downregulation of INHBA. In certain embodiments, the administration of the compositions of the invention having an up-regulation of^ CTGF and downregulation of INHBA have an antiaging effect. 7 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application Inhibin subunit beta A (INHBA) gene plays a role in the proliferation of cells in human epidermis. INHBA / Activin-A expression levels in the human epidermis increased with age. In certain embodiments, decrease in expression and / or activity of INHBA would likely have an antiaging effect on the skin. Connective tissue growth factor (CTGF) is involved in pro-collagen^ production and / or collagen degradation. The up-regulation and / or enhanced activity of CTGF is associated with increased collagen production and / or decrease in collagen degradation. The increased collagen production has an important antiaging effect on the appearance of the skin. In certain embodiments of the invention, the administration of the composition comprising 4,6,4’- trihydroxy-3’-methoxyaurone leads to at least about ten (10) fold up regulation of CTFG. In certain^ embodiments of the invention, the administration of the composition comprising 4,6,4’- trihydroxy-3’-methoxyaurone leads to at least about fifty (50) fold downregulation of INHBA. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone leads to formation of fine lines and / or wrinkles on the skin. The prevention of formation of fine lines and / or wrinkles on the skin may be due to the increased amount of collagen.^ In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone leads to formation downregulation of matrix metalloproteinase 3 (MMP3) and / or matrix metalloproteinase 9 (MMP9). The downregulation of expression and / or activity of MMP3 and / or MMP9 may result in decrease of breakdown of collagen. In certain embodiments of the invention, the administration of the composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone^ leads to at least about ten (10) fold downregulation of MMP3. In certain embodiments of the invention, the administration of the composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone leads to at least about three (3) fold downregulation of MMP9. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone leads to an anti-inflammatory response. The anti-inflammatory response may be^ in the skin of the subject receiving a composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone results in about three (3) to about seventy-five (75) times down-regulation in the expression and / or activity of one or more genes involved in inflammatory responses. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone^ leads to downregulation of prostaglandin-endoperoxide synthase 2 (PTGS2), interleukin 1 receptor 8 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application type 2 (IL1R2), interleukin 36 receptor antagonist (IL36RN), interleukin 1 alpha (IL1A), interleukin 1 beta (IL1B), interleukin 36 gamma (IL36G), and / or interleukin (IL6). PTGS2, IL1R2, IL36RN, IL1A, IL1B, IL36G, and / or IL6 play a role in the inflammatory responses in the body. Downregulation of PTGS2, IL1R2, IL36RN, IL1A, IL1B, IL36G, and / or IL6 may result in^ reduction in the inflammatory responses in the subject. In certain embodiments of the invention, the administration of the composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone leads to at least about thirty (30) fold downregulation of PTGS2. In certain embodiments of the invention, the administration of the composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone leads to at least about sixty (60) fold downregulation of^ IL1R2. In certain embodiments of the invention, the administration of the composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone leads to at least about twenty (20) fold downregulation of IL36RN. In certain embodiments of the invention, the administration of the composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone leads to at least about fifteen (15) fold downregulation of IL1A. In certain embodiments of the invention, the administration of the^ composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone leads to at least about twenty (20) fold downregulation of IL1B. In certain embodiments of the invention, the administration of the composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone leads to at least about fifteen (15) fold downregulation of IL36G. In certain embodiments of the invention, the administration of the composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone leads to at least about ten (10) fold^ downregulation of IL6. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone leads to inhibition of melanogenesis. Melanogenesis is synthesis of melanin. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone leads to downregulation of IL6 and / or PTGS2. IL6 and / or PTGS2 are involved in^ synthesis of melanin. Downregulation of IL6 and / or PTGS2 lead to inhibition of melanogenesis. In certain embodiments of the invention, the administration of the composition comprising 4,6,4’- trihydroxy-3’-methoxyaurone leads to at least about ten (10) fold downregulation of IL6. In certain embodiments of the invention, the administration of the composition comprising 4,6,4’- trihydroxy-3’-methoxyaurone leads to at least about thirty (30) fold downregulation of PTGS2. 9 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone to a subject leads to the treatment of prevention of a topical condition of the subject through the modulation of levels of expression or activity of one or genes that may be involved in the topical condition. In certain embodiments, administration of a composition comprising 4,6,4’-^ trihydroxy-3’-methoxyaurone alters one or more of a function related with the modulated genes, wherein the one or more function is selected from the group consisting of: (i) maintenance of skin barrier, (ii) collagen expression, (iii) collagen degradation, (iv) inflammation, (v) tissue atrophy, (vi) muscle loss, and (vii) melanin production. IV. BRIEF DESCRIPTION OF DRAWINGS ^ FIG.1A is a picture of the solution with 0.5% w / w 4,6,4’-trihydroxy-3’-methoxyaurone in oil / water emulsion. FIG.1B is a picture of 0.73% w / w 4,6,4’-trihydroxy-3’-methoxyaurone solubilized in dimethyl isosorbide. FIG.2 is a chart of stability of 4,6,4’-trihydroxy-3’-methoxyaurone in dimethyl^ isosorbide. FIG.3 provides the data pertaining to gene modulation expression. V. DETAILED DESCRIPTION 4,6,4’-trihydroxy-3’-methoxyaurone 4,6,4’-trihydroxy-3’-methoxyaurone is a naturally produced material found in Asparagus^ genociado and Limonium species. 4,6,4’-trihydroxy-3’-methoxyaurone is a traditionally used herbicide. The chemical structure of 4,6,4’-trihydroxy-3’-methoxyaurone is provided below: 10 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application 4,6,4’-trihydroxy-3’- as: 4,6-dihydroxy-2Z-[(4- hydroxy-3-methoxyphenyl)methylene]-3(2H)-benzofuranone. Compositions of 4,6,4’-trihydroxy-3’-methoxyaurone ^ In one aspect, the invention provides compositions comprising 4,6,4’-trihydroxy-3’- methoxyaurone. In certain embodiments, the invention provides compositions comprising 4,6,4’- trihydroxy-3’-methoxyaurone that are suitable for administration on the skin of the subject. The invention recognizes that 4,6,4’-trihydroxy-3’-methoxyaurone is poorly soluble or insoluble in water. The invention also recognizes that 4,6,4’-trihydroxy-3’-methoxyaurone is also^ poorly soluble or insoluble in oil, for example, 4,6,4’-trihydroxy-3’-methoxyaurone is insoluble in Helianthus Annuus (Sunflower) Seed Oil. The invention recognizes that the solvent used for preparing 4,6,4’-trihydroxy-3’-methoxyaurone compositions should be any solvent acceptable to be used in cosmetic formulations. In certain embodiments, 4,6,4’-trihydroxy-3’-methoxyaurone is dissolved in a solvent^ selected from a group consisting of: 1,2 heptanediol, 1,2 hexanediol, 1,2 propanediol, butylene glycol, C15-19alkane, capric / caprylic triglyceride, dibutyl adipate, diisopropyl adipate, dimethyl isosorbide, dipropylene glycol, ethanol, ethoxydiglycol, isoamyl laurate, isohexadecane, isopentyldiol, isopropyl myristate, isoproyl lauryl sarcosinate, jojoba oil, meadowfoam seed oil, mineral oil, neopentyl glycol diethylhexanoate, octyldodecanol, oleyl alcohol, pentylene glycol,^ phenylpropanol, polysorbate 20, propanediol, safflower seed oil, squalene, sunflower oil, t-butyl alcohol, tributyl citrate, tributyl-O-acetylcitrate, tri-C15-19 alkyl citrate, triethyl citrate, triethyl O- acetylcitrate, and triisostearin. In certain preferred embodiments of the invention, 4,6,4’-trihydroxy-3’-methoxyaurone is dissolved in a solvent selected from a group consisting of: dimethyl isosorbide, ethoxydiglycol, 11 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application isopropyl lauryl sarcosinate, pentylene glycol, propanediol, 1,2-hexanediol, and / or butylene glycol. In certain preferred embodiments, 4,6,4’-trihydroxy-3’-methoxyaurone is dissolved in dimethyl isosorbide. Table 1 provides the solubility data for 4,6,4’-trihydroxy-3’-methoxyaurone in several solvents. ^ Table 1: Solubility of 4,6,4’-trihydroxy-3’-methoxyaurone Solvent Solubility (%w / w) As evident from the data provided above, 4,6,4’-trihydroxy-3’-methoxyaurone is soluble in dimethyl isosorbide. FIG. 1B provides a picture of a solution of 4,6,4’-trihydroxy-3’- methoxyaurone dissolved in dimethyl isosorbide. ^ Thus, in certain embodiments, the composition comprises an emulsion. Preferably, the emulsion is oil / water emulsion. FIG.1A provides a picture of 4,6,4’-trihydroxy-3’-methoxyaurone formulated in oil / water emulsion. In certain embodiments, the composition further comprises dimethyl isosorbide. In certain embodiments, the 4,6,4’-trihydroxy-3’-methoxyaurone is dissolved in dimethyl isosorbide. The^ compositions of the invention are wherein the composition is stable under storage for at least two (2) months. This is beneficial because the compositions of the invention may be stored prior to administration to the subjects. In certain embodiments, wherein the compositions of the invention have less than about 20% degradation when stored at 4 ^ or 25 ^ for 2 months. In certain embodiments, the compositions of the invention have less than about 25% degradation when stored^ at 40 ^ or 50 ^ for 2 months. FIG. 2 provides the data for stability of 4,6,4’-trihydroxy-3’- methoxyaurone dissolved in dimethyl isosorbide. The invention beneficially provides that solutions of 4,6,4’-trihydroxy-3’-methoxyaurone dissolved in dimethyl isosorbide have increased 12 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application solubility and are shelf stable. Since 4,6,4’-trihydroxy-3’-methoxyaurone is not soluble in sunflower oil and other commonly used solvents, the increased solubility in dimethyl isosorbide is surprising and unexpected. In certain embodiments, the composition comprises 4,6,4’-trihydroxy-3’-methoxyaurone^ in a concentration of about 5 nM to about 2500 nM. In certain embodiments, the composition comprises 4,6,4’-trihydroxy-3’-methoxyaurone in a concentration of about 10 nM to about 2000 nM. In certain embodiments, the composition comprises 4,6,4’-trihydroxy-3’-methoxyaurone in a concentration of about 20nM nM to about 1000 nM. In certain embodiments, the composition comprises 4,6,4’-trihydroxy-3’-methoxyaurone in a concentration of about 10 nM to about 20 nM.^ In certain embodiments, in the compositions of the invention, 4,6,4’-trihydroxy-3’-methoxyaurone is present in a concentration of about 0.0001% to about 5.0% w / w. In certain other embodiments, 4,6,4’-trihydroxy-3’-methoxyaurone is present in a concentration of 0.0005% to about 2.0% w / w. In certain other embodiments, 4,6,4’-trihydroxy-3’-methoxyaurone is present in a concentration of 0.0007% to about 1.0% w / w. In certain other embodiments, 4,6,4’-trihydroxy-3’-^ methoxyaurone is present in a concentration of 0.001% to about 0.75% w / w. In certain other embodiments, 4,6,4’-trihydroxy-3’-methoxyaurone is present in a concentration of 0.001% to about 0.75% w / w. In certain other embodiments, 4,6,4’-trihydroxy-3’-methoxyaurone is present in a concentration of about 0.5% w / w. In certain aspects, the compositions of the invention may be administered as a topical^ composition on the skin of the subject. The compositions of the invention may be included in any formulation suitable for topical administration. In certain embodiments, the composition of the invention is a fluid, emulsion, encapsulation, suspension, solid, semi-solid, jelly, paste, gel, hydrogel, ointment, lotion, emulsion, cream, foam, mousse, liquid, spray, suspension, dispersion, powder, aerosol, color cosmetic, and / or hair treatment. In certain embodiments, the compositions^ of the invention also include excipients. These excipients may be selected from a group consisting of: solvent, emulsifier, preservative, antioxidant, emollient, thickening agent, penetration enhancer, surfactant, diluent, filler, carrier, and / or pH control agent. In certain embodiments, the preservative in the composition is an antimicrobial preservative or chelating agent. In certain embodiments, the solvent of the invention is dimethyl isosorbide. 13 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application The compositions of the invention may be prepared by various methods. As an example, the compositions may be prepared by dissolving, dispersing, etc. 4,6,4’-trihydroxy-3’- methoxyaurone as provided herein and optional excipients in a carrier (e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol or the like) or a solvent to form a solution, colloid, liposome,^ emulsion, complexes (including inclusion complexes), coacervate, or suspension. In certain embodiments, the compositions of the current invention can also contain auxiliary substances such as wetting agents, emulsifying agents, co-solvents, solubilizing agents, pH buffering agents, and the like (e.g., sodium acetate, sodium citrate, cyclodextrins and derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, hydroxyethylpiperazine and the like). In certain^ embodiments, the compositions of the invention may further include one or more additional excipients selected from a group consisting of: carriers, excipients, or diluents including, but not limited to, absorbents, anti-irritants, antibacterials, anti-acne agents, antioxidants, coloring agents / pigments, emollients (moisturizers), emulsifiers, film-forming / holding agents, fragrances, leave-on exfoliants, prescription drugs, preservatives, scrub agents, silicones, skin-^ identical / repairing agents, slip agents, sunscreen actives, surfactants / detergent cleansing agents, penetration enhancers, and thickeners. Absorbents are substances which are added to topical products to take up water and oil- soluble dissolved or finely dispersed substances. Topical absorbents can also be used as thickeners in a wide variety of formulations including facial creams, lipsticks, shampoos and calamine^ lotions. In some embodiments, absorbents may include, but are not limited to, alcohol (ethyl alcohol, methanol, isopropyl alcohol, SD alcohol [especially denatured alcohol] and benzyl alcohol), alumina (aluminum oxide), aluminum chlorohydrate, aluminum hydroxide, aluminum magnesium silicate, aluminum silicate, aluminum starch octenylsuccinate, aluminum sulfate, ammonium chloride, bentonite, bismuth oxychloride, boron nitride, calcium carbonate, carnauba^ wax, charcoal, China clay, clay, Copernicia cerifera wax, cornstarch, fuller's earth, hydrolyzed corn starch, iron powder, kaolin, lithium magnesium sodium silicate, magnesium, magnesium carbonate, magnesium hydroxide, montmorillonite, nylon-12, rice starch, silica, silicate, silk powder, silt, sodium carbonate, sodium polyacrylates, and zeolite. Anti-Irritants are substances which are added to topical products to reduce inflammation,^ especially, the inflammation resulting from the application of the product itself. The excipients 14 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application included as anti-irritants that perform the function of anti-irritants or anti-inflammatories may have more than one function. For example, many antioxidants also function as anti-irritants. In some embodiments, anti-irritants and / or antioxidants may include, but are not limited to, Acacia senegal, acetylsalicylic acid, Achillea millefolium, adenosine, citric acid, adenosine triphosphateAloe^ barbadensis, aloe barbadensis leaf juice extract, aloe extract, aloe juice, hydrogenated olive oil, hydrogenated palm glycerides, hydrolyzed silk, hydroquinone, aloe vera, and / or alpha bisabolol. In certain embodiments, the compositions of the invention may further include humectants. Humectants (or moisturizers) are important cosmetic ingredients that prevent loss of moisture thereby retaining the skin’s natural moisture. Some humectants also can actively attract moisture.^ In certain embodiments, the humectants may be selected from a group consisting of sodium hyaluronate, sodium acetylated hyaluronate, hydrolyzed sodium hyaluronate, propylene glycol, hexylene glycol, and butylene glycol. In certain embodiments, the compositions of the invention may further include slip agents. The term “slip agent” is used to describe a range of ingredients which can help other ingredients^ spread over the skin and penetrate into the skin. Slip agents can also have humectant (hygroscopic) properties. In some embodiments, slip agents may include, but are not limited to, amodimethicone, bis-PEG-18 methyl ether dimethyl silane, bis-phenylpropyl dimethicone, butylene glycol, cetyl dimethicone, cetyl dimethicone copolyol, cetyl PEG / PPG-10 / 1-dimethicone, cyclohexasiloxane, cyclomethicone, cyclopentasiloxane, cyclotetrasiloxane, decylene glycol, diisostearoyl^ trimethylolpropane siloxy silicate, dimethicone, dimethicone copolyol, dimethicone crosspolymer, dimethiconol, dipropylene glycol, hexylene glycol, hydrolyzed silk, isododecane, methicone, methyl trimethicone, methylsilanol mannuronate, methylsilanol PEG-7 glyceryl cocoate, Good, PEG-10 dimethicone, PEG-10 dimethicone / vinyl dimethicone crosspolymer, PEG-12 dimethicone, PEG / PPG-18 / 18 dimethicone, PEG / PPG-20 / 15 dimethicone, pentylene glycol,^ phenyl trimethicone, polymethylsilsesquioxane, PPG-3 benzyl ether myristate, silica dimethyl silylate, silk powder, siloxane, simethicone, sorbitol, stearyl dimethicone, stearyl methicone, triethoxycaprylylsilane, trimethylsiloxysilicate, xylitol, and zinc stearate. In certain embodiments, the compositions of the invention may further include diluents, and / or carriers. Diluents and / or carriers may include, but are not limited to, polyethylene glycols^ (such as PEG200, PEG300, PEG400, PEG540, PEG600, PEG1450 or mixtures thereof) and 15 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application coconut oils (such as propylene glycol dicaprate, coco-caprylate / caprate, propylene glycol dicaprylate / dicaprate, caprylic / capric triglyceride, caprylic / capric / lauric triglyceride, caprylic / capric / linoleic triglyceride, tricaprin, tricaprylin, glyceryl trioleate, neopentyl glycol dicaprylate / dicaprate, caprylic / capric / palmitic / stearic triglceride, or mixtures thereof). ^ In certain embodiments, the compositions of the invention may further include emollients. Emollients are supple, waxlike, lubricating, thickening substances which are added to cosmetic / dermatological products to prevent water loss and have a softening and soothing effect on the skin.^ In some embodiments, emollients may include, but are not limited to, 10- hydroxydecanoic acid, acetyl glyceryl ricinoleate, acetylated castor oil, acetylated hydrogenated^ cottonseed glyceride, acetylated lanolin,^ acetylated lanolin alcohol, acetylated palm kernel glycerides, agar, algae extract, algin, almond oil, squalane, squalene, Į-glucan oligosaccharide, amodimethicone, Anacystis nidulans extract, apricot kernel oil, arachidic acid, arachidonic acid, arachidyl alcohol, arachidyl propionate, C10-30 cholesterol / lanosterol esters, C12-15 alkyl benzoate, C12-18 acid triglyceride, C18-36 acid triglyceride, candelilla wax, Cannabis sativa L. oil,^ caprylic / capric triglyceride, caprylyl methicone, carrot oil, Carthamus tinctorius oil, Carya illinoensis oil, castor isostearate succinate, castor oil, Caulerpa taxifolia extract, and / or cephalin. In certain embodiments, the compositions of the invention may further include film- forming / holding agents. Film-Forming / Holding agents are substances which are added to^ cosmetic / dermatological products to help leave a pliable, cohesive, and continuous covering over the skin. This film has water-binding properties and leaves a smooth feel on skin. In some embodiments, film-forming / holding agents may include, but are not limited to, acrylate, acrylates copolymer, acrylates / C10-30 alkyl acrylate crosspolymer, acrylates / dimethicone copolymer, adipic acid / neopentyl glycol / trimellitic anhydride copolymer, allyl methacrylates crosspolymer,^ carnauba wax, cellulose gum, Copernicia cerifera wax, dextrin, diisopropyl adipate, glyceryl polymethacrylate, hydrolyzed wheat protein, hydroxyethylcellulose, locust bean, neopentyl glycol diheptanoate, PEG-40 hydrogenated castor oil, polyacrylamide, polyacrylate-17, polyglucuronic acid, polyglyceryl methacrylate, polyisobutene, polymethyl methacrylate, polyquaternium-10, polyquaterniums, polyvinyl alcohol, polyvinylpyrrolidone, propylene carbonate, PVM / MA^ (polyvinyl methyl ether / maleic acid) decadiene crosspolymer, PVP [poly(vinylpyrrolidone)] 16 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application copolymer, PVP / dimethylaminoethyl-methacrylate, sodium carbomer, sodium polyacrylate, styrene / acrylates copolymer, triethoxycaprylylsilane crosspolymer, VA (vinyl acetate) / crotonates, VA / crotonates copolymer, VP (vinylpyrrolidone) / eicosene copolymer, and VP / hexadecene copolymer. ^ In certain embodiments, the compositions of the invention may further include excipients related to the fragrance of the formulation. Fragrance ingredients are a single or a blend of volatile and / or fragrant plant oils (or synthetically derived oils) that impart aroma and odor to cosmetic / dermatological products. The level of fragrance to use varies according to the product type. In some embodiments, the composition of the formulation may contain up to about 0.01%^ fragrance by weight. In some embodiments, fragrances (e.g., synthetic and fragrant plant extracts) may include, but are not limited to, Acacia farnesiana extract, Aerocarpus santalinus, amyl cinnamate, amyl salicylate, amyris oil, Anethum graveolens, Angelica archangelica root oil, anisaldehyde, anise, balm mint extract, balsam peru, bay leaf oil, bergamot oil, bitter orange flower, bois de rose oil, bois oil, Boswellia carterii, butylphenyl^ methylpropional, cananga extract, Cananga odorata, cardamom, cedarwood, cherry extract, Citrus aurantifolia, Citrus aurantium, Citrus aurantium extract, Citrus medica limonium, clary oil, Commiphora myrrha extract, coriander, Cucurbitea peponis, cyclamen aldehyde, dill extract, ethyl vanillin, eugenol, farnesol, farnesyl acetate, Ferula galbaniflua, fir needle oil, floralozone, Foeniculum vulgare extract, frankencense extract, galbanum, Gardenia florida^ extract, grapefruit oil, guaiac wood, Guaiacum officinale, hedione, hexyl cinnamal, hyssop, Illicium vernum, Iris florentina extract, jasmine oil, Jasminium grandiflorum, jonquil extract, Laurus nobilis, lauryl lactate, lavandin oil, Lavandula angustifolia, Lavandula officinalis, lavender extract and oil, lemon, lemon balm, lemongrass oil, Levisticum officinale root extract, lime oil and extract, limonene, linalool, Litsea cubeba, mandarin orange oil or extract,^ marjoram, Melissa officinalis, Mentha piperita, Mentha spicata, Mentha viridis, menthol, menthone, menthoxypropanediol, and menthyl lactate. In certain embodiments, the composition of the invention may further include preservatives. Preservatives are substances which prevent bacterial, microbial or fungal contamination of cosmetic / dermatological products thereby increasing the product's shelf life and^ consumer safety. Some of these agents also have stabilizing effects able to preserve the function 17 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application of various active ingredients including anti-oxidants (vitamins), emulsifiers and surfactants. In some embodiments, preservatives may include, but are not limited to, 1,2-hexanediol, benzoic acid, benzothonium chloride, borax, bronopol, butylparaben, caprylyl glycol, chlorophene, chloroxylenol, chlorphenesin, decylene glycol, dehydroacetic acid, diazolidinyl urea, DMDM^ hydantoin, ethylhexylglycerin, ethylparaben, formaldehyde-releasing preservative, Germaben II, hoelen, hydroxyacetophenone, imidazolidinyl urea, iodopropynyl butylcarbamate, isobutylparaben, methylchloroisothiazolinone, methyldibromo glutaronitrile, Methylisothiazolinone, methylparaben, o-cymen-5-ol, phenoxyethanol, phenoxyisopropanol, phytosphingosine, polyaminopropyl biguanide, potassium sorbate, propylparaben, quaternium-15,^ sodium benzoate, sodium citrate, sodium dehydroacetate, sodium hexametaphosphate, sodium hydroxymethylglycinate, phenethyl alcohol, sodium lactobionate, sodium metabisulfite, sodium sulfite, sorbic acid, and styrax benzoin. In certain aspects of the invention, the pharmaceutical composition is an emulsion. The emulsion compositions of the invention may further include emulsifiers. Emulsifiers are^ substances which are added to cosmetic / dermatological products to help keep unlike ingredients (such as oil and water) from separating in an emulsion. There are 2 types of emulsifiers. Oil-in- water (o / w) emulsifiers keep oil drops packed in water, while water-in-oil (w / o) emulsifiers keep water drops packed in oil. W / O emulsifiers are used for a fatty feel (e.g. night & sun protection creams). O / W emulsifiers are used more in moisturizing products (e.g. body lotions, day creams).^ In certain embodiments, the compositions of the invention may further include surfactants. Surfactants are compounds that lower surface tension or interfacial tension. Reducing the surface tension allows a liquid to spread easier while reducing the interfacial tension (interfacial meaning between two faces) between water and an oil / lipid allows them to mix. Surfactants may have a be anionic, amphoteric, non-ionic, and / or quaternary agents. Surfactants form the base of all personal^ cleansing products and can also have wetting, conditioning, defatting, emulsifying, & thickening effects. In some embodiments, emulsifiers, surfactants, and detergents may include, but are not limited to, ammonium laureth sulfate, ammonium lauryl sulfate, arachidyl glucoside, behenic acid, bis-PEG-18 methyl ether dimethyl silane, C20-40 pareth-40, cocamidopropyl betaine, cocamidopropyl dimethylamine, cocamidopropyl hydroxysultaine, coco-glucoside, coconut oil,^ decyl glucoside, dicetyl phosphate, dihydrocholeth-30, disodium cocoamphodiacetate, disodium 18 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application cocoyl glutamate, disodium lauraminopropionate, glyceryl behanate, hydrogenated vegetable glycerides citrate, isohexadecane, isostearamide DEA, lauramphocarboxyglycinate, laureth-23, laureth-4, laureth-7, lauryl PEG-9 polydimethylsiloxyethyl dimethicone, lauryl alcohol, lauryl glucoside, magnesium laureth sulfate, magnesium oleth sulfate, myristic acid, nonoxynols, oleic^ acid, oleth 10, palm kernel acid, palmitic acid, PEG-60 almond glycerides, PEG-75 shea butter glycerides, PEG 90M, PEG-10 dimethicone, PEG-10 dimethicone / vinyl dimethicone crosspolymer, PEG-10 rapeseed sterol, PEG-100 stearate, PEG-12 dimethicone, PEG-120 methyl glucose dioleate, PEG-20 methyl glucose sesquistearate, PEG-40 stearate, PEG-60 hydrogenated castor oil, PEG-7 glyceryl cocoate, PEG-8, PEG-80 sorbitan laurate, PEG / PPG-17 / 6 copolymer^ (polyethylene glycol / polypropylene glycol-17 / 6 copolymer), PEG / PPG-18 / 18 dimethicone, PEG / PPG-20 / 15 dimethicone, poloxamer 184, Poloxamer 407, poloxamers, polyglyceryl-3 beeswax, polyglyceryl-4 isostearate, polyglyceryl-6 isostearate, polysorbate 20, polysorbate 60, polysorbate 80, potassium cetyl phosphate, potassium hydroxide, potassium myristate, PPG-12 buteth-16, PPG-26-Buteth-26, Salvia officinalis, Saponaria officinalis extract, soapwort, sodium^ C14-16 olefin sulfonate, sodium cetearyl sulfate, sodium cocoamphoacetate, sodium cocoate, sodium cocoyl glutamate, sodium cocoyl isethionate, sodium dilauramidoglutamide lysine, sodium hexametaphosphate, sodium hydroxide, sodium laureth sulfate, sodium laureth-13 carboxylate, sodium lauroamphoacetate, sodium lauroyl lactylate, sodium lauroyl sarcosinate, sodium lauryl glucose carboxylate, sodium lauryl sulfate, sodium methyl cocoyl taurate, sodium^ methyl taurate, sodium myreth sulfate, sodium palm kernelate, sodium palmate, sodium PEG-7 olive oil carboxylate, sodium trideceth sulfate, steareth-20, TEA-lauryl sulfate (triethanolamine- lauryl sulfate), and tribehenin PEG-20 esters. In certain embodiments, the compositions of the invention may further include one or more thickeners. Thickeners are substances which are added to cosmetic / dermatological products to^ enhance the consistency, volume and viscosity of cosmetic products, thereby providing more stability and better performance. While some thickeners have also emulsifying or gelling properties, the majority of thickeners have the ability to retain water on the skin and act therefore as moisturizers. Thickeners can be completely natural like waxes but also synthetic or semi- synthetic. In some embodiments, thickeners may include, but are not limited to, Acacia senegal,^ acetyl glyceryl ricinoleate, acetylated castor oil, acetylated hydrogenated cottonseed glyceride, 19 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application acetylated palm kernel glycerides, acrylates / steareth-20 methacrylate copolymer, agar, Ahnfeltia concinna extract, ahnfeltia extract, Alaria esculenta, algae, algae extract, algin, alkyloamides, Althaea rosea, Althea officinalis, alumina, aluminum hydroxide, aluminum stearate, ammonium acryloyldimethyltaurate / VP copolymer, Anacystis nidulans extract, arachidic acid,^ arachidonic acid, arachidyl alcohol, arachidyl propionate, arrowroot, artemia extract, Ascophyllum nodosum, ascorbyl methylsilanol pectinate, Asparagopsis armata extract, beeswax, behenic acid, behentrimonium chloride, behenyl alcohol, bis-diglyceryl polyacyladipate, bismuth oxychloride, C12-15alkyl benzoate, C12-18acid triglyceride, C13-14isoparaffin, C18-36acid triglyceride, candelilla wax, caprylic / capric triglyceride, carbomer, carbopol, carnauba wax, carrageenan, Caulerpa^ taxifolia extract, cellulose, Cellulose gum, cephalin, Cera alba, ceresin, ceteareth-20, cetearyl alcohol, cetearyl ethylhexanoate, cetearyl glucoside, cetearyl octanoate, cetyl alcohol, cetyl dimethicone copolyol, cetyl hydroxyethylcellulose, cetyl palmitate, cetyl PEG / PPG-10 / 1- dimethicone, chlorella, Chondrus crispus, cocamide DEA and MEA, cocoglycerides, Codium tomentosum extract, Copernicia cerifera wax, Corallina officinalis extract, Corallina , DEA oleth-^ 10 phosphate, diethanolamine (DEA), di-PPG-3 myristyl ether adipate, dimethicone crosspolymer, dimethicone / vinyl dimethicone crosspolymer, polyacrylate crosspolymer, and / or dimer dilinoleyl dimer dilinoleate. In certain embodiments, the compositions of the invention may further include one or more chelators. Chelating agents are any of numerous ingredients that bind with metal ions or metallic^ compounds, preventing them from adhering to a surface (such as skin, hair, or clothing) or causing contamination, such as in the case of trace amounts of iron. In some embodiments, chelators may include, but are not limited to tetrasodium EDTA, sodium phytate, and / or teathydroxypropyl ethylenediamine. In certain embodiments, the excipients included in the composition are water, dimethyl^ isosorbide, glycerin, caprylic / capric triglyceride, propanediol, sunflower seed oil, ethoxydiglycol, squalane, sodium acrylate copolymer, cetearyl alcohol, phenoxyethanol, glyceryl stearate, capryloyl glycerin / sebacic acid copolymer, diheptyl succinate, naringenin, lecithin, decylene glycol, pentylene glycol, cetearyl glucoside, shea butter, palmitic acid, arachidyl alcohol, behenyl alcohol, arachidyl glucoside, phenethyl alcohol, 1,2-hexanediol, hydrogenated olive oil, olea^ europaea (olive) fruit oil, olea europaea (olive) oil unsponifiables, hydroxyethyl acrylate / sodium 20 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application acryloyldimethyl taurate copolymer, citric acid, sodium acetylated hyaluronate, sodium hyaluronate crosspolymer, sodium phytate, hydrolyzed sodium hyaluronate, and / or ethylhexylglycerin. Table 2 provides a list of excipients, along with their approximate concentrations, that may^ be used in the exemplary compositions of the invention. is provided below: Table 2: Excipients in an exemplary composition: Ingredient %w / w Water 40 - 80 21 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application Sodium Acetylated Hyaluronate 0 - 1 Sodium Hyaluronate 0 - 1 i H l l 1 4, 6,4 -trihydroxy-3 -methoxyaurone for treatment of topical conditions: Advantageously, it was discovered that 4,6,4’-trihydroxy-3’-methoxyaurone impacts the genes and signaling pathways involved in several topical conditions. In one aspect, the invention^ provides methods of using the compositions for treating, protecting, and / or altering (e.g., improving) the condition and / or aesthetic appearance of skin, including, for example, treating, preventing, ameliorating, reducing and / or eliminating fine lines and / or wrinkles of skin and / or improving the aesthetic appearance of fine lines and / or wrinkles of skin. In certain embodiments, the compositions of the invention lead to increase in skin and / or hair resiliency. In certain^ embodiments, the compositions of the invention lead to increase in elasticity of the skin. In certain embodiments, the compositions of the invention prevent skin damage. In one aspect, the invention includes a composition for topical administration comprising an effective amount of 4,6,4’-trihydroxy-3’-methoxyaurone. The effective amount of 4,6,4’- trihydroxy-3’-methoxyaurone is an amount of 4,6,4’-trihydroxy-3’-methoxyaurone that would be^ effective in treating, ameliorating, or otherwise impacting the underlying condition of the skin. In certain aspects of the invention, the compositions comprising 4,6,4’-trihydroxy-3’- methoxyaurone promote skin lightening and / or brightening. In certain embodiments, the compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone at least a concentration of 0.01% w / w, have at least about 5% higher L value (reflecting the lightening of the skin), as compared to^ skin treated with a corresponding composition lacking 4,6,4’-trihydroxy-3’-methoxyaurone. In certain aspects of the invention, the compositions comprising 4,6,4’-trihydroxy-3’- methoxyaurone demonstrate antioxidant activity. In certain embodiments, the compositions of the invention, the antioxidant activity of 4,6,4’-trihydroxy-3’-methoxyaurone is demonstrated at concentrations of about 0.00005% w / w or higher. Advantageously, the compositions of the^ invention comprising 4,6,4’-trihydroxy-3’-methoxyaurone, demonstrating antioxidant activity, are 22 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application effective for treating and / or preventing oxidation damage. In certain embodiments, the compositions of the invention comprising 4,6,4’-trihydroxy-3’-methoxyaurone, demonstrating antioxidant activity, are effective for treatment of skin and / or hair damaged by reactive oxygen species and protection from other environmental aggressors that may damage the skin of the^ subject. In certain other embodiments, the compositions of the invention comprising 4,6,4’- trihydroxy-3’-methoxyaurone, demonstrating antioxidant activity, are effective for prevention of skin and / or hair damage by reactive oxygen species, including the damage caused by environmental aggressors. As demonstrated from the data provided in Examples 2 and 3, compositions comprising^ 4,6,4’-trihydroxy-3’-methoxyaurone are effective in demonstrating robust antioxidant activity in both aqueous and organic solvent systems. The IC50 values for antioxidant activity calculated in aqueous and organic solvent systems was 0.00034% w / w and 0.0013% system respectively. These results demonstrate that compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone have robust antioxidant activity. In certain embodiments, the compositions comprising 4,6,4’-^ trihydroxy-3’-methoxyaurone are useful in treatment of conditions caused by oxidation or excessive oxidation in the skin of the subject. In certain embodiments, the compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone are administered for treatment and / or prevention of skin or hair damage by reaction oxygen species and protection from environmental aggressors. In certain aspects of the invention, the compositions comprising 4,6,4’-trihydroxy-3’-^ methoxyaurone demonstrate elastase enzyme inhibition. In certain embodiments, the compositions of the invention, the elastase enzyme inhibition activity of 4,6,4’-trihydroxy-3’-methoxyaurone is demonstrated at concentrations of about 0.005% w / w or higher. As evident from the data provided in Example 4, compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone have robust elastase enzyme inhibition activity. Indeed, the IC50 value calculated for elastase enzyme inhibition activity^ of 4,6,4’-trihydroxy-3’-methoxyaurone was 0.015%. Advantageously, the compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone, demonstrating elastase enzyme inhibition activity, are effective for promoting the elasticity of the skin. In certain embodiments, the compositions of the invention comprising 4,6,4’-trihydroxy-3’- methoxyaurone, demonstrating elastase enzyme inhibition, are effective in reduction of fine lines^ and / or wrinkles in the skin. In certain embodiments, the compositions of the invention comprising 23 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application 4,6,4’-trihydroxy-3’-methoxyaurone, demonstrating elastase enzyme inhibition, are effective in prevention of formation of fine lines and / or wrinkles in the skin. In certain aspects of the invention, the compositions comprising 4,6,4’-trihydroxy-3’- methoxyaurone demonstrate inhibition of glycation. In certain embodiments, the compositions of^ the invention, the glycation inhibition activity of 4,6,4’-trihydroxy-3’-methoxyaurone is demonstrated at concentrations of about 0.005% w / w or higher. As evident from the data provided in Example 5, compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone have robust glycation inhibition. Indeed, the calculated IC50value for glycation inhibition by compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone is 0.001%. Advantageously, the compositions^ comprising 4,6,4’-trihydroxy-3’-methoxyaurone, demonstrating glycation inhibition activity, are effective for supporting and promoting skin and / or hair resiliency. Genetic expression and / or activity modulation In certain aspects of the invention, a composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone modulates expression of one more genes that is related to a topical condition. In^ certain embodiments, administration of composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone alters one or more of a function related with the modulated genes, wherein the one or more function is selected from the group consisting of: (i) collagen expression, (ii) formation of fines lines or wrinkles on the skin, (iii) inflammation, (iv) melanin synthesis, and (v) collagen degradation. ^ Advantageously, it has been determined that the administration of compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone alter expression and / or activity of one or more genes related to a topical condition and / or skin appearance. In certain embodiments, the one or more genes are selected from a group consisting of: (i) INHBA, (ii) PTGS2, (iii) IL1R2, (iv) IL36RN, (v) IL1A, (vi) IL1B, (vii) IL36G, (viii) CTGF, (ix) IL6, (x) MMP3, and (xi) MMP9. In^ certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone leads to up-regulation of CTGF. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone leads to down-regulation of INHBA, PTGS2, IL1R2, IL36RN, IL1A, IL1B, IL36G, IL6, MMP3, and / or MMP9. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone 24 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application have an antiaging effect on the skin. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone inhibits melanogenesis. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone has an anti- inflammatory effect, thereby, reducing inflammation and improving the appearance of the skin.^ In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone leads to up-regulation of CTGF and downregulation of INHBA. In certain embodiments, the administration of the compositions of the invention having an up-regulation of CTGF and downregulation of INHBA have an antiaging effect. Inhibin subunit beta A (INHBA) gene encodes a member of the TGF-beta (transforming^ growth factor-beta) superfamily of proteins. The encoded preproprotein is proteolytically processed to generate a subunit of the dimeric activin and inhibin protein complexes. These complexes activate and inhibit, respectively, follicle stimulating hormone secretion from the pituitary gland. INHBA plays a role in the proliferation of cells in human epidermis. INHBA / Activin-A expression levels in the human epidermis increased with age. In certain^ embodiments, decrease in expression and / or activity of INHBA would likely have an antiaging effect on the skin. As demonstrated in the data in FIG.3, in certain embodiments of the invention, the administration of the composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone leads to at least about fifty (50) fold downregulation of INHBA. Connective tissue growth factor (CTGF) is involved in pro-collagen production and / or^ collagen degradation. The up-regulation and / or enhanced activity of CTGF is associated with increased collagen production and / or decrease in collagen degradation. The increased collagen production has an important antiaging effect on the appearance of the skin. As demonstrated in the data in FIG. 3, in certain embodiments of the invention, the administration of the composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone leads to at least about ten (10) fold up regulation^ of CTFG. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone leads to formation of fine lines and / or wrinkles on the skin. The prevention of formation of fine lines and / or wrinkles on the skin may be due to the increased amount of collagen. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’- 25 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application methoxyaurone leads to downregulation of matrix metalloproteinase 3 (MMP3) and / or matrix metalloproteinase 9 (MMP9). MMP3 and MMP9 encode for matrix metalloproteinase-3 and matrix metalloprotease-9 respectively, which are part of matrix metalloprotease family of proteins. Proteins in this family^ are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. The encoded preproprotein is proteolytically processed to generate the mature protease. This secreted protease breaks down the interstitial collagens, including types I, II, and III. The gene is part of a cluster of MMP genes on chromosome 11. Thus, MMP3 and / or^ MMP9 are also involved in collagen degradation. As demonstrated in the data provided in FIG.3, in certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone caused at least ten (10) fold decrease in expression and / or activity of MMP3 and at least three (3) fold decrease in expression and / or activity of MMP9. This decrease in expression of MMP3 and / or MMP9 results in decrease in the rate of degradation of collagen, which is^ responsible for maintaining strength and integrity of the skin. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone leads to an anti-inflammatory response. The anti-inflammatory response may be in the skin of the subject receiving a composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’-^ methoxyaurone results in about three (3) to about seventy (70) times down-regulation in the expression and / or activity of one or more genes involved in inflammatory responses. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone leads to downregulation of prostaglandin-endoperoxide synthase 2 (PTGS2), interleukin 1 receptor type 2 (IL1R2), interleukin 36 receptor antagonist (IL36RN), interleukin 1 alpha (IL1A),^ interleukin 1 beta (IL1B), interleukin 36 gamma (IL36G), and / or interleukin (IL6). PTGS2, IL1R2, IL36RN, IL1A, IL1B, IL36G, and / or IL6 play a role in the inflammatory responses in the body. Downregulation of PTGS2, IL1R2, IL36RN, IL1A, IL1B, IL36G, and / or IL6 may result in reduction in the inflammatory responses in the subject. Prostaglandin-endoperoxide synthase (PTGS), also known as cyclooxygenase, is the key^ enzyme in prostaglandin biosynthesis, and acts both as a dioxygenase and as a peroxidase. There 26 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application are two isozymes of PTGS: a constitutive PTGS1 and an inducible PTGS2, which differ in their regulation of expression and tissue distribution. This gene encodes the inducible isozyme. It is regulated by specific stimulatory events, suggesting that it is responsible for the prostanoid biosynthesis involved in inflammation and mitogenesis. As demonstrated in the data provided in^ FIG.3, in certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone leads to at least about thirty (30) fold downregulation of PTGS2. IL1R2 encodes for a protein in the interleukin 1 receptor family. The protein encoded by this gene is a cytokine receptor that belongs to the interleukin 1 receptor family. This protein binds interleukin alpha (IL1A), interleukin beta (IL1B), and interleukin 1 receptor, type^ I(IL1R1 / IL1RA), and acts as a decoy receptor that inhibits the activity of its ligands. The proteins of this family are play a role in the inflammatory response. As demonstrated in the data provided in FIG.3, in certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy- 3’-methoxyaurone leads to at least about sixty (60) fold downregulation of IL1R2. IL36RN encodes for a protein that is a member of the interleukin 1 cytokine family. This^ cytokine was shown to specifically inhibit the activation of NF-kappaB induced by interleukin 1 family, member 6 (IL1F6). This gene and eight other interleukin 1 family genes form a cytokine gene cluster on chromosome 2. Two alternatively spliced transcript variants encoding the same protein have been reported. As demonstrated in the data provided in FIG. 3, in certain embodiments, the administration of the composition comprising 4,6,4’-trihydroxy-3’-^ methoxyaurone leads to at least about twenty (20) fold downregulation of IL36RN. IL1A encodes for a protein that is a member of the interleukin 1 cytokine family. This cytokine is a pleiotropic cytokine involved in various immune responses, inflammatory processes, and hematopoiesis. This cytokine is produced by monocytes and macrophages as a proprotein, which is proteolytically processed and released in response to cell injury, and thus induces^ apoptosis. This gene and eight other interleukin 1 family genes form a cytokine gene cluster on chromosome 2. It has been suggested that the polymorphism of these genes is associated with rheumatoid arthritis and Alzheimer's disease. As demonstrated in the data provided in FIG. 3, in certain embodiments, the administration of the composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone leads to at least about fifteen (15) fold downregulation of IL1A. 27 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application IL1B also encodes for a protein that is a member of the interleukin 1 cytokine family. As demonstrated in the data provided in FIG. 3, in certain embodiments, the administration of the composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone leads to at least about twenty (20) fold downregulation of IL1B. ^ IL36G also encodes for a protein that is a member of the interleukin 1 cytokine family. As demonstrated in the data provided in FIG. 3, in certain embodiments, the administration of the composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone leads to at least about fifteen (15) fold downregulation of IL36G. IL6 encodes a cytokine that functions in inflammation and the maturation of B cells. In^ addition, the encoded protein has been shown to be an endogenous pyrogen capable of inducing fever in people with autoimmune diseases or infections. The protein is primarily produced at sites of acute and chronic inflammation, where it is secreted into the serum and induces a transcriptional inflammatory response through interleukin 6 receptor, alpha. The functioning of this gene is implicated in a wide variety of inflammation-associated disease states, including susceptibility to^ diabetes mellitus and systemic juvenile rheumatoid arthritis. As demonstrated in the data provided in FIG. 3, in certain embodiments, the administration of the composition comprising 4,6,4’- trihydroxy-3’-methoxyaurone leads to at least about ten (10) fold downregulation of IL6. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone leads to inhibition of melanogenesis. Melanogenesis is synthesis of melanin. In^ certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone leads to downregulation of IL6 and / or PTGS2. IL6 and / or PTGS2 are involved in synthesis of melanin. Downregulation of IL6 and / or PTGS2 lead to inhibition of melanogenesis. In certain embodiments of the invention, the administration of the composition comprising 4,6,4’- trihydroxy-3’-methoxyaurone leads to at least about ten (10) fold downregulation of IL6. In certain^ embodiments of the invention, the administration of the composition comprising 4,6,4’- trihydroxy-3’-methoxyaurone leads to at least about thirty (30) fold downregulation of PTGS2. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone to a subject leads to the treatment of prevention of a topical condition of the subject through the modulation of levels of expression or activity of one or genes that may be involved in 28 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application the topical condition. In certain embodiments, administration of a composition comprising 4,6,4’- trihydroxy-3’-methoxyaurone alters one or more of a function related with the modulated genes, wherein the one or more function is selected from the group consisting of: (i) maintenance of skin barrier, (ii) collagen expression, (iii) collagen degradation, (iv) inflammation, (v) tissue atrophy,^ (vi) muscle loss, and (vii) melanin production. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone downregulates the proteins involved in melanogenesis signaling pathway. In certain embodiments, administration of a composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone to a subject leads to the treatment of prevention of a topical condition of the subject^ through the modulation of levels of expression or activity of one or genes that may be involved in the topical condition. In certain embodiments, administration of a composition comprising 4,6,4’- trihydroxy-3’-methoxyaurone alters one or more of a function related with the modulated genes, wherein the one or more function is selected from the group consisting of: (i) maintenance of skin barrier, (ii) collagen expression, (iii) collagen degradation, (iv) inflammation, (v) tissue atrophy,^ (vi) muscle loss, and (vii) melanin production. Treatment of topical conditions The current invention recognizes that the compositions comprising 4,6,4’-trihydroxy-3’- methoxyaurone is beneficial for treating, protecting and / or improving the condition and / or aesthetic appearance of skin. For example, the compositions of the invention may be effective for^ altering the aesthetic appearance of skin associated with or affected by, or for treating or preventing, fine lines and / or wrinkles of skin caused by, for example, cellular senescence, environmental damage or dermatoheliosis. The invention also provides methods for stimulating skin cell renewal, increasing cell or tissue regeneration, promoting fibroblast proliferation and synthesizing elastin, collagen, proteoglycans, and / or new connective tissue, thereby reducing or^ improving the appearance of wrinkles, restoring elasticity, resiliency, and / or suppleness to the skin. The compositions of the invention provided herein can be useful for improving the aesthetic appearance of skin. Such improvements can include, but are not limited to, all outward visibly and tactilely perceptible manifestations as well as any other macro or micro effects due to 29 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application skin aging and damage. Such manifestations and effects can be induced or caused by intrinsic factors and / or extrinsic factors, e.g., chronological aging, environmental damage, climate, sun (UV) exposure, smoking, drugs, alcohol consumption, jetlag, night work, changes in circadian rhythm, pregnancy, menopause, genetic factors, nutritional factors and / or deficiencies,^ dehydration, stress, allergies (e.g., to plants, animals, medications, and other substances), exposure to industrial and / or household chemicals, indoor heating and cooling, various disorders and diseases such as arteriosclerosis, diabetes, heart disease, liver disease, and obesity, thinning of the outer layer of skin, decreases in the number of pigment-containing cells, increases in the size of pigment-containing cells, changes in the connective tissue, and reduction in the strength and^ elasticity of the skin. The aesthetic appearance of skin can be improved, for example, by improving the appearance of skin associated with or affected by one or more of wrinkles, dry skin, sensitive skin; wrinkling and sagging; acne; vitiligo (skin condition in which there is a loss of brown color (pigment) from areas of skin); fine lines, wizened skin, thinning of the dermis, the degradation of^ collagen fibers, flaccid skin, thinned skin, and skin exposed to ultraviolet radiation. In some embodiments, the compositions of the invention can improve the aesthetic appearance of skin by decreasing the appearance of fine lines in the skin; creating a more youthful appearance of the skin; decreasing bags and / or rings around the eyes; increasing or restoring the elasticity, resiliency, and / or suppleness of the skin; increasing the apparent thickness, elasticity, flexibility, radiance,^ glow, and plumpness of the skin; improving the fineness of the skin texture; improving the appearance of wrinkles, lined, dry, flaky, aged, and / or photodamaged skin; treating or preventing photodamaged skin; reducing the signs of skin aging; reducing the appearance of hyperpigmentation; treating or preventing hyperpigmentation; treating or preventing pigment deposition in the skin (e.g., that caused by UV exposure); reducing the appearance of skin^ discolorations; and whitening, lightening, and / or bleaching the skin. In certain embodiments, the compositions may be used for care, treatment, cleansing, and / or protective products for facial or body skin; anti-wrinkle or anti-aging compositions; skin firming compositions; skin lightening compositions; compositions for irritated skin; sunscreen compositions, artificial tanning (self-tanning) compositions or after-sun 30 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application care compositions; scalp care compositions; shaving preparation compositions; depilatory compositions; or make-up products for the skin of the face or body. In certain embodiments, the compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone are administered for altering the aesthetic appearance of skin associated with or affected by, or^ treating or preventing, a skin condition / disorder (e.g., a skin condition / disorder accompanied with a loss of skin elasticity). In certain embodiments, the compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone are administered for improving the barrier function and viability of the skin. In certain embodiments, the compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone^ are administered for altering the aesthetic appearance of skin associated with or affected by wrinkling, sagging, and / or a loss of skin elasticity. In certain embodiments, the compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone are administered for altering the aesthetic appearance of skin associated with or affected by deteriorations in skin viscoelasticity. ^ In certain embodiments, the compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone are administered for altering the aesthetic appearance of skin associated with or affected by one or more of wrinkles and / or fine lines, wizened skin, a lack of elasticity and / or of tonus of the skin, thinning of the dermis, degradation of collagen fibers, flaccid skin, thinned skin, and the internal degradation of the skin following exposure to ultraviolet radiation. ^ In certain embodiments, the compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone are administered for decreasing the appearance of fine lines and / or wrinkles in the skin. In certain embodiments, the compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone are administered for decreasing the appearance of bags and / or rings around the eyes. In certain embodiments, the compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone^ are administered for reducing the appearance of hyperpigmentation. 31 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application In certain embodiments, the compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone are administered for improving or increasing one or more of the thickness, elasticity, flexibility, radiance, glow, and plumpness of the skin. In certain embodiments, the compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone^ are administered for improving the fineness of skin texture. In certain embodiments, the compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone are administered for improving the appearance of wrinkled, lined, dry, flaky, aged or photodamaged skin. In certain embodiments, the compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone^ are administered for altering the aesthetic appearance of skin associated with or affected by skin discolorations. Methods of Administration: In one aspect, the invention provides methods of administration of the compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone. In certain embodiments, the invention the^ compositions of the invention are designed for topical administration. In certain embodiments, the compositions of the invention may be administered as a topical composition on the skin of the subject. The compositions of the invention may be included in any formulation suitable for topical administration. In certain embodiments, the composition of the invention is a fluid, emulsion, encapsulation, suspension, solid, semi-solid, jelly, paste, gel,^ hydrogel, ointment, lotion, emulsion, cream, foam, mousse, liquid, spray, suspension, dispersion, powder, aerosol, color cosmetic, and / or hair treatment. In certain other embodiments, the compositions comprising 4,6,4’-trihydroxy-3’- methoxyaurone may be prepared and used in the form of an aerosol spray, cream, emulsion, solid, liquid, dispersion, foam, oil, gel, lotion, mousse, ointment, powder, patch, pomade, solution, pump^ spray, stick, towelette, soap, or other forms commonly employed in the art of topical administration and / or cosmetic and skin care formulation. The compositions can be in an emulsion form. In addition, compounds provided herein used in the compositions provided herein can be used in color cosmetic compositions such as foundation makeups, blushes, eyeshadows, mascaras, 32 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application concealers, eyeliners, lip colors, nail colors, and so on. Other cosmetic compositions can include perfumes, lipsticks, fingernail and toenail polish, eye and facial makeup, towelettes, deodorants, hand sanitizer, baby products, bath oils, bubble baths, and butters. In certain embodiments, the compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone^ are administered over an area of about 1.0 ^g / cm2to about 100 ^g / cm2. In certain embodiments, the compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone are administered for a duration till the desired impact in amelioration or prevention of a topical condition is realized. In certain embodiments, the composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone comprises an effective amount of 4,6,4’-trihydroxy-3’-methoxyaurone. The^ effective amount of 4,6,4’-trihydroxy-3’-methoxyaurone is an amount of 4,6,4’-trihydroxy-3’- methoxyaurone that results in the desired result in the condition of the skin. In certain embodiments, the composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone is administered once a day. In certain embodiments, the composition comprising 4,6,4’-trihydroxy-3’- methoxyaurone is administered twice a day. In certain embodiments, the composition comprising^ 4,6,4’-trihydroxy-3’-methoxyaurone is administered thrice a day. In certain embodiments, the composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone is administered once every two days. In certain embodiments, the composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone is administered once every three days. Examples: ^ Example 1: Exemplary composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone: Table 3 provides an exemplary formulation of 4,6,4’-trihydroxy-3’-methoxyaurone: Table 3: Exemplary composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone: Ingredient %w / w 1 2 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application Sodium Arcylates Copolymer 0.7500 Cetearyl Alcohol 0.6214 Example 2: ABTS antioxidant assay: The 2,2'-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt (ABTS) antioxidant assay is designed to evaluate the antioxidant activity of compositions comprising^ 4,6,4’-trihydroxy-3’-methoxyaurone in an aqueous medium. ABTS+ solution is generated as a free radical and used to measure relative ability of a compound to scavenge free radicals. Reduction of the absorbance at 734 nm was standardized to solvent control as an indication of ABTS+ scavenging. 34 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application Table 4, provided below, demonstrates the results from these experiments: Table 4: ABTS (aqueous antioxidant assay) radical inhibition 4,6,4’-trihydroxy-3’-methoxyaurone % Radical concentration (%w / w) Inhibition As evident from the results provided in Table 4 above, compositions comprising 4,6,4’-^ trihydroxy-3’-methoxyaurone demonstrates antioxidant activity at concentrations at low as 0.00008% w / w in aqueous systems. The calculated IC50 value is: 0.00034% w / w. Example 3: DPPH Antioxidant Activity assay The 2,2-diphenyl-1-picrylhydrazyl (DPPH) antioxidant assay is designed to evaluate the antioxidant activity of compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone in an organic^ medium. 2,2-diphenyl-1-picrylhydrazyl (DPPH) is a stable free radical used to evaluate free radical scavenging capacity of a material. In the presence of an antioxidant DPPH is reduced, resulting in the formation of a colorless solution. Reduction of absorbance at 517 nm is standardized to solvent control as an indication of DPPH scavenging. ^ Table 5, provided below, provides the antioxidant activity data. Table 5: DPPH Radical Inhibition 4,6,4’-trihydroxy-3’-methoxyaurone % Radical Inhibition 35 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application As evident from the results provided in Table 5 above, compositions comprising 4,6,4’- trihydroxy-3’-methoxyaurone demonstrate antioxidant activity at concentrations at low as 0.007% w / w in organic solvent systems. The calculated IC50 value is: 0.0013% w / w. Example 4: Elastase enzyme inhibition: ^ The assay was conducted to evaluate the elastase enzyme inhibition activity of compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone. Neutrophil infiltration and neutrophil elastase are both increased in the skin in response to UV stress. Neutrophil elastase has been shown to activate MMP-1 and MMP-2 collagenase in response to low dose UV exposure, harming the extracellular matrix and contributing to^ photoaging and wrinkle formation. The activity of elastase can be further upregulated in the presence of reactive oxygen species. Therefore, inhibition of this enzyme, particularly in combination with antioxidant activity, is effective in delaying wrinkle development and aiding in maintaining skin integrity. This assay is measures release of 4-nitroaniline from an Me-Suc-Ala- Ala-Pro-Val-pNA by human neutrophil elastase and can be quantified at 405 nm by comparing to^ the solvent control. Table 6 provides the elastase inhibition activity of compositions comprising 4,6,4’- trihydroxy-3’-methoxyaurone: Table 6: Elastase enzyme inhibition 4,6,4’-trihydroxy-3’- ^ As evident from the data provide in Table 6, compositions comprising 4,6,4’-trihydroxy- 3’-methoxyaurone inhibits elastase enzyme activity as low at 0.008% w / w. The IC50 calculated for elastase inhibition activity was 0.015%. 36 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application Example 5: Glycation inhibition assay: The assay was conducted to evaluate the glycation inhibition activity of compositions comprising 4,6,4’-trihydroxy-3’-methoxyaurone. Nonenzymatic glycation can occur when glucose reacts with proteins, forming a Schiff^ base intermediate that subsequently undergoes Amadori rearrangement to form glycosylated proteins, when they react with skin proteins to form Advanced Glycation End products (AGE). AGE formation can result in loss of skin elasticity and impaired cellular function. The glycation inhibition ability of a compound is measured by change in fluorescence at excitation / emission of 360 nm / 420 nm relative to solvent control. ^ Table 7 provides the data for glycation inhibition. Table 7: Glycation Inhibition 4,6,4’-trihydroxy-3’- % Enzyme Inhibition methoxyaurone concentration As evident from the data provided in Table 7, compositions comprising 4,6,4’-trihydroxy- 3’-methoxyaurone inhibits glycation as low as 0.0007% w / w. The IC50value calculated for^ glycation inhibition is 0.001%. Incorporation by Reference References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, web contents, publicly accessible databases, have been made throughout this disclosure. All such documents are hereby incorporated herein by reference in their^ entirety for all purposes. 37 ^ Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application Equivalents Various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including references to the scientific and patent literature cited herein.^ The subject matter herein contains important information, exemplification and guidance that can be adapted to the practice of this invention in its various embodiments and equivalents thereof. 38 ^

Claims

Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application CLAIMS:

1. A composition for topical administration comprising an effective amount of 4,6,4’- trihydroxy-3’-methoxyaurone.

2. The composition of claim 1, wherein the composition comprises an emulsion.

3. The composition of claim 2, wherein the emulsion is an oil / water emulsion.

4. The composition of claim 1, wherein the composition further comprises dimethyl isosorbide.

5. The composition of claim 1, wherein the 4,6,4’-trihydroxy-3’-methoxyaurone is dissolved in dimethyl isosorbide.

6. The composition of claim 5, wherein the composition is stable under storage for at least two (2) months.

7. The composition of claim 5, wherein the composition has less than about 20% degradation when stored at 4 ^ or 25 ^ for two (2) months.

8. The composition of claim 5, wherein the composition has less than about 25% degradation when stored at 40 ^ for two (2) months.

9. The composition of claim 1, wherein the 4,6,4’-trihydroxy-3’-methoxyaurone is present in a concentration of about 0.0001% to about 5.0% w / w.

10. The composition of claim 1, wherein the 4,6,4’-trihydroxy-3’-methoxyaurone is present in a concentration of about 0.0005% to about 2.0% w / w.

11. The composition of claim 1, wherein the 4,6,4’-trihydroxy-3’-methoxyaurone is present in a concentration of 0.0007% to about 1.0% w / w. 39 ^Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application 12. The composition of claim 1, wherein the 4,6,4’-trihydroxy-3’-methoxyaurone is present in a concentration of about 0.001% to about 0.75% w / w.

13. The composition of claim 1, wherein 4,6,4’-trihydroxy-3’-methoxyaurone is present in a concentration of about 0.5% w / w.

14. The composition of claim 1, wherein the composition is selected from a group consisting of: fluid, emulsion, encapsulation, suspension, solid, semi-solid, jelly, paste, gel, hydrogel, ointment, lotion, emulsion, cream, foam, mousse, liquid, spray, suspension, dispersion, powder, aerosol, color cosmetic, hair treatment, and any combination thereof.

15. The composition of claim 1, wherein the composition further comprises one or more excipients selected from a group consisting of: solvent, emulsifier, preservative, antioxidant, emollient, thickening agent, penetration enhancer, surfactant, diluent, filler, carrier, and / or pH control agent.

16. The composition of claim 15, wherein the preservative is an antimicrobial preservative or chelating agent.

17. The composition of claim 15, wherein the solvent is dimethyl isosorbide.

18. The composition of claim 1, wherein the composition further comprises one or more excipients selected from a group consisting of: water, dimethyl isosorbide, glycerin, caprylic / capric triglyceride, propanediol, sunflower seed oil, ethoxydiglycol, squalane, sodium acrylate copolymer, cetearyl alcohol, phenoxyethanol, glyceryl stearate, capryloyl glycerin / sebacic acid copolymer, diheptyl succinate, naringenin, lecithin, decylene glycol, pentylene glycol, cetearyl glucoside, shea butter, palmitic acid, arachidyl alcohol, behenyl alcohol, arachidyl glucoside, phenethyl alcohol, 1,2-hexanediol, hydrogenated olive oil, olea europaea (olive) fruit oil, olea europaea (olive) oil unsponifiables, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, citric acid, sodium acetylated hyaluronate, sodium hyaluronate crosspolymer, sodium phytate, hydrolyzed sodium hyaluronate, and ethylhexylglycerin. 40 ^Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application 19. The composition of claim 1, wherein the composition comprises about 50% to about 70% water (w / w) and about 10% to about 30% (w / w) dimethyl isosorbide.

20. The composition of claim 1, wherein the composition is: Ingredient %w / w Water 40 - 8041 ^Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application Ethylhexylglycerin 0 - 1 21.of a composition comprising an effective amount of 4,6,4’-trihydroxy-3’-methoxyaurone.

22. The method of claim 21, wherein the administration of the composition prevents fine lines or wrinkles on skin of the subject.

23. The method of claim 21, wherein the administration of the composition leads to supporting firmness and elasticity of skin of the subject.

24. The method of claim 21, wherein the administration of the composition leads to the prevention of skin and hair damaged by reactive oxygen species.

25. The method of claim 21, wherein the administration of the composition leads to protection from environmental aggressors on skin.

26. The method of claim 21, wherein the administration of the composition leads to supporting skin elasticity.

27. The method of claim 21, wherein the topical condition is glycation.

28. The method of claim 21, wherein the administration of the composition leads increase in skin and / or hair resiliency.

29. The method of claim 21, wherein the administration of the composition leads to increase in elasticity of skin.

30. The method of claim 21, wherein the administration of the composition leads to prevention of skin damage.

31. The method of claim 21, wherein the composition is administered topically.

32. The method of claim 21, wherein the composition comprises an emulsion. 42 ^Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application 33. The method of claim 32, wherein the emulsion is an oil / water emulsion.

34. The method of claim 21, wherein the composition further comprises dimethyl isosorbide.

35. The method of claim 21, wherein the 4,6,4’-trihydroxy-3’-methoxyaurone is dissolved in dimethyl isosorbide.

36. The method of claim 35, wherein the composition is stable under storage for at least two (2) months.

37. The method of claim 35, wherein the composition has less than about 20% degradation when stored at 4 ^ or 25 ^ for two (2) months.

38. The method of claim 35, wherein the composition has less than about 30% degradation when stored at 40 ^ for two (2) months.

39. The method of claim 21, wherein the 4,6,4’-trihydroxy-3’-methoxyaurone is present in a concentration of about 0.0001% to about 5.0% w / w.

40. The method of claim 21, wherein the 4,6,4’-trihydroxy-3’-methoxyaurone is present in a concentration of about 0.0005% to about 2.0% w / w.

41. The method of claim 21, wherein the 4,6,4’-trihydroxy-3’-methoxyaurone is present in a concentration of 0.0007% to about 1.0% w / w.

42. The method of claim 21, wherein the 4,6,4’-trihydroxy-3’-methoxyaurone is present in a concentration of about 0.001% to about 0.75% w / w.

43. The method of claim 21, wherein 4,6,4’-trihydroxy-3’-methoxyaurone is present in a concentration of about 0.5% w / w.

44. The method of claim 21, wherein the composition is selected from a group consisting of: fluid, emulsion, encapsulation, suspension, solid, semi-solid, jelly, paste, gel, hydrogel, 43 ^Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application ointment, lotion, emulsion, cream, foam, mousse, liquid, spray, suspension, dispersion, powder, aerosol, color cosmetic, and any combination thereof.

45. The method of claim 21, wherein the composition further comprises one or more excipients selected from a group consisting of: solvent, emulsifier, preservative, antioxidant, emollient, thickening agent, penetration enhancer, surfactant, diluent, filler, carrier and / or pH control agent.

46. The method of claim 45, wherein the preservative is an antimicrobial preservative.

47. The method of claim 45, wherein the solvent is dimethyl isosorbide.

48. The method of claim 21, wherein the composition further comprises one or more excipients selected from a group consisting of: water, dimethyl isosorbide, glycerin, caprylic / capric triglyceride, propanediol, sunflower seed oil, ethoxydiglycol, squalane, sodium acrylate copolymer, cetearyl alcohol, phenoxyethanol, glyceryl stearate, capryloyl glycerin / sebacic acid copolymer, diheptyl succinate, naringenin, lecithin, decylene glycol, pentylene glycol, cetearyl glucoside, shea butter, palmitic acid, arachidyl alcohol, behenyl alcohol, arachidyl glucoside, phenethyl alcohol, 1,2-hexanediol, hydrogenated olive oil, olea europaea (olive) fruit oil, olea europaea (olive) oil unsponifiables, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, citric acid, sodium acetylated hyaluronate, sodium hyaluronate crosspolymer, sodium phytate, hydrolyzed sodium hyaluronate, and ethylhexylglycerin.

49. The method of claim 21, wherein the composition comprises about 50% to about 70% water (w / w) and about 10% to about 30% (w / w) dimethyl isosorbide.

50. The method of claim 21, wherein the composition is: Ingredient %w / w44 ^Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application Helianthus Annuus (Sunflower) Seed Oil 0 - 5 Ethoxydiglycol 0 - 5 l 251. The composition of claim 1, wherein the composition is anhydrous.

52. The composition of claim 1, wherein the composition comprises oil as the only solvent.

53. The method of claim 21, wherein the composition is anhydrous.

54. The method of claim 21, wherein the composition comprises oil as the only solvent. 45 ^Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application 55. A method of modulating expression of one or more genes by administration of a composition comprising 4,6,4’-trihydroxy-3’-methoxyaurone, wherein at least one of the genes is related to a topical condition 56. The method of claim 55, wherein the one or more genes are selected from a group consisting of: (i) INHBA, (ii) PTGS2, (iii) IL1R2, (iv) IL36RN, (v) IL1A, (vi) IL1B, (vii) IL36G, (viii) CTGF, (ix) IL6, (x) MMP3, and (xi) MMP9.

57. The method of claim 55, wherein the administration of the composition leads to up- regulation of CTGF.

58. The method of claim 55, wherein the administration of the composition leads to down- regulation of INHBA, PTGS2, IL1R2, IL36RN, IL1A, IL1B, IL36G, IL6, MMP3, and / or MMP9.

59. The method of claim 55, wherein the administration of the composition has antiaging effect on the skin.

60. The method of claim 55 or 59, wherein the administration of composition leads to up- regulation of CTGF and downregulation of INHBA.

61. The method of claim 55, wherein the administration of the composition prevents degradation of collagen.

62. The method of claim 61, wherein the prevention of degradation of collagen prevents the formation of fine lines and / or wrinkles on skin.

63. The method of claim 61, wherein the downregulation of MMP3 and / or MMP9 results in prevention of collagen degradation.

64. The method of claim 55, wherein the administration of the composition leads to an anti- inflammatory response. 46 ^Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application 65. The method of claim 64, wherein the downregulation of PTGS2, IL1R2, IL36RN, IL1A, IL1B, IL36G, and / or IL6 results in an anti-inflammatory response.

66. The method of claim 55, wherein the administration of the composition leads to inhibition of melanogenesis.

67. The method of claim 66, wherein the downregulation of IL6 and PTGS2 leads to decreased melanin synthesis activity.

68. The method of claim 55, wherein the administration of the composition to a subject leads to the treatment or prevention of a topical condition of the subject.

69. The method of claim 57, wherein the administration of the composition results in at least ten (10) fold up regulation of expression and / or activity of CTFG.

70. The method of claim 58, wherein the administration of the composition results in about three (3) to about seventy five (75) times down-regulation in the expression and / or activity of INHBA, PTGS2, IL1R2, IL36RN, IL1A, IL1B, IL36G, IL6, MMP3, and / or MMP9.

71. The method of claim 63, wherein the administration of composition results in about three (3) to about thirteen (13) times down-regulation in the expression of MMP3 and / or MMP9.

72. The method of claim 66, wherein the administration of composition results in about ten (10) to about seventy five (75) times down-regulation in the expression of PTGS2, IL1R2, IL36RN, IL1A, IL1B, IL36G, and / or IL6.

73. The method of claim 67, wherein the administration of composition results in about five (5) to about forty (40) times down-regulation in the expression of IL6 and PTGS2. 47 ^Attorney Docket No.: DEBU-016 / 01WO 37396 / 140 Patent Application 74. The method of claim 55, wherein the administration of composition alters one or more of a function related with the modulated genes, wherein the one or more function is selected from the group consisting of: (i) collagen expression, (ii) formation of fines lines or wrinkles on the skin, (iii) inflammation, (iv) melanin synthesis, and (v) collagen degradation.

75. The method of claim 55, wherein the composition comprises from about 1 nM to about 2500 nM 4,6,4’-trihydroxy-3’-methoxyaurone.

76. The method of claim 55, wherein the composition comprises from about 10 nM to about 2000 nM 4,6,4’-trihydroxy-3’-methoxyaurone.

77. The method of claim 55, wherein the composition comprises from about 20 nM to about 1000 nM 4,6,4’-trihydroxy-3’-methoxyaurone.

78. The method of claim 55, wherein the composition comprises from about 10 nM to about 20 nM 4,6,4’-trihydroxy-3’-methoxyaurone.

79. The method of claim 55, wherein the composition comprises about 16.65 nM 4,6,4’- trihydroxy-3’-methoxyaurone.

80. The method of claim 55, wherein the composition further comprises a solvent.

81. The method of claim 55, wherein the solvent is selected from a group consisting of: dimethyl isosorbide, ethoxydiglycol, isopropyl lauryl sarcosinate, pentylene glycol, propanediol, 1,2-hexanediol, and / or butylene glycol. 48 ^